CEFTRIAXONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ceftriaxone, and when can generic versions of Ceftriaxone launch?
Ceftriaxone is a drug marketed by Acs Dobfar, Agila Speclts, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu, Samson Medcl, Sandoz, Sandoz Inc, Teva, Wockhardt, Astral, Cephazone Pharma, Deva Holding As, Epic Pharma Llc, Hikma Farmaceutica, Teva Pharms Usa, B Braun, Baxter Hlthcare, Anda Repository, and Hikma. and is included in thirty-seven NDAs.
The generic ingredient in CEFTRIAXONE is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ceftriaxone
A generic version of CEFTRIAXONE was approved as ceftriaxone sodium by ANDA REPOSITORY on January 20th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CEFTRIAXONE?
- What are the global sales for CEFTRIAXONE?
- What is Average Wholesale Price for CEFTRIAXONE?
Summary for CEFTRIAXONE
| US Patents: | 0 |
| Applicants: | 24 |
| NDAs: | 37 |
| Finished Product Suppliers / Packagers: | 14 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 175 |
| Patent Applications: | 5,278 |
| Drug Prices: | Drug price information for CEFTRIAXONE |
| DailyMed Link: | CEFTRIAXONE at DailyMed |
Recent Clinical Trials for CEFTRIAXONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tata Memorial Centre | Phase 2 |
| Ministry of Health, France | Phase 3 |
| Assistance Publique Hopitaux De Marseille | Phase 3 |
Pharmacology for CEFTRIAXONE
| Drug Class | Cephalosporin Antibacterial |
US Patents and Regulatory Information for CEFTRIAXONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065169-002 | May 9, 2005 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Deva Holding As | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 210197-001 | Jan 12, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bedford | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065465-004 | Aug 18, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Anda Repository | CEFTRIAXONE SODIUM | ceftriaxone sodium | INJECTABLE;INJECTION | 091117-001 | Jan 20, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
